Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$59.29 – $74.00
7% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $132.6M | $134.4M | $127.6M | $148.1M | $147.8M | $157.6M | $208.5M | $232.5M |
| Cost of revenue | $20.3M | $18.9M | $24.1M | $24.1M | $24.6M | $26.8M | $38.7M | $39.3M |
| Gross profit | $112.3M | $115.5M | $103.6M | $124.0M | $123.2M | $130.8M | $169.9M | $193.2M |
| Gross margin | 84.7% | 86.0% | 81.2% | 83.7% | 83.3% | 83.0% | 81.5% | 83.1% |
| R&D | $104.9M | $102.7M | $97.4M | $93.2M | $73.8M | $77.9M | $77.1M | $106.0M |
| Operating income | −$24.1M | −$17.2M | −$8.2M | $1.2M | $18.5M | $19.2M | $61.2M | $51.6M |
| EBITDA | −$22.2M | −$14.3M | −$6.0M | $3.6M | $21.7M | $23.2M | $66.3M | $51.0M |
| Net income | −$31.4M | −$22.4M | −$14.7M | −$6.8M | $12.1M | $10.5M | $77.6M | $40.2M |
| Net margin | -23.7% | -16.7% | -11.5% | -4.6% | 8.2% | 6.6% | 37.2% | 17.3% |
| EPS (diluted) | -2.89 | -2.08 | -1.43 | -0.58 | 1.02 | 0.86 | 5.83 | 3.14 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $252M | $4.27 | $4.07–$4.52 | 1 |
| 2027 | $258M | $2.98 | $2.84–$3.16 | 1 |
| 2028 | $217M | $0.76 | $0.73–$0.81 | 1 |
| 2029 | $198M | $3.35 | $3.19–$3.54 | 1 |
Forward consensus · source: Financial Modeling Prep
BASILEA PHARM AG AKT SHS
No one on the platform currently holds BPMUF.
No tracked institution reports a position in BPMUF as of their last filing.
No one on the platform has traded BPMUF yet.
| +0.00% |
| $497M |
| — |
| MDCLFMedinCell S.A. | $34.39 | +0.00% | $1.2B | — |
| PTCHFPureTech Health plc | $1.70 | +0.00% | $414M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 39.1× earnings vs its 18.5× historical median P/E.
Fair value ≈ $28.43 · price $60.27 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.